IONSHealthcare · BiotechnologyThe 23 Wall Street analysts covering Ionis Pharmaceuticals, Inc. hold a median 12-month price target of $90 — +57.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 13 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Ionis Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (86): The share price has been relatively steady.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IONS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +57.2% from it.
Of the 20 most recent actions, 1 moved their price target up and 9 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | JP Morgan | Maintains | Overweight | $72 → $76 |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | $125 → $115 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | $100 → $95 |
| 21 July 2026 | Guggenheim | Maintains | Buy | — |
| 21 July 2026 | Guggenheim | Maintains | Buy | $106 → $89 |
| 16 July 2026 | Wolfe Research | Downgrade | Peer Perform | — |
| 16 July 2026 | Wolfe Research | Downgrade | Peer Perform | — |
| 13 July 2026 | RBC Capital | Maintains | Outperform | — |
| 13 July 2026 | RBC Capital | Maintains | Outperform | $100 → $85 |
| 10 July 2026 | Barclays | Maintains | Overweight | — |
| 10 July 2026 | Barclays | Maintains | Overweight | $115 → $90 |
| 10 July 2026 | Canaccord Genuity | Maintains | Buy | $110 → $95 |
| 10 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 10 July 2026 | Citigroup | Maintains | Buy | $115 → $100 |
| 10 July 2026 | Citigroup | Maintains | Buy | — |
| 10 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 July 2026 | HC Wainwright & Co. | Maintains | Buy | $130 → $125 |
| 10 July 2026 | Morgan Stanley | Maintains | Overweight | $130 → $110 |
| 10 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 9 July 2026 | Jefferies | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IONS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 14% of US stocks
Cheaper than 5% of US stocks
Cheaper than 87% of US stocks
Higher than 6% of US stocks
Higher than 99% of US stocks
Higher than 18% of US stocks
Higher than 8% of US stocks
Higher than 12% of US stocks
Higher than 25% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ionis Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ionis stock has plunged 30%. The company's Q2 revenue fell, though last year's figures included a large one-time payment, and the earnings report also showed other signs of trouble.
Why it matters — An Ionis watcher would care because the sharp share-price decline and Q2 earnings report signal concerning financial results for the company.
SBS Law announced that investors in Ionis Pharmaceuticals, Inc. have the opportunity to join a fraud investigation concerning the company. The notice, distributed via Business Wire, invites affected IONS shareholders to participate in the probe.
Why it matters — An active fraud investigation involving Ionis could have legal and reputational implications for the company that shareholders and watchers should monitor.
Ionis Pharmaceuticals director Hayden purchased 20,000 shares for a total value of approximately $1.1 million across multiple execution windows, increasing their total direct and indirect equity holdings by 34%.
Why it matters — IONS watchers pay attention because a director's sizable share purchase can signal insider confidence in the company's prospects.
Ionis Pharmaceuticals beat Q2 revenue and earnings estimates, with commercial growth offsetting tough comparisons, and reaffirmed its 2026 outlook.
Why it matters — A watcher of Ionis would care because the company exceeded quarterly expectations on both revenue and earnings while maintaining confidence in its longer-term 2026 guidance.
Seeking Alpha published the transcript of Ionis Pharmaceuticals' Q2 2026 earnings call, providing a record of management's discussion of the company's financial results and business developments.
Why it matters — Earnings call transcripts offer Ionis investors direct insight into management's commentary on quarterly performance and strategic direction.
The 23 Wall Street analysts covering Ionis Pharmaceuticals, Inc. have a median 12-month price target of $90, with estimates ranging from $66 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 23 analysts covering Ionis Pharmaceuticals, Inc., 19 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ionis Pharmaceuticals, Inc. 48 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Aug 2026, Ionis Pharmaceuticals, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (86 of 100).
No one can know that. What the data says: the median 12-month target from 23 analysts implies +57.2% from the last close, and Ticker Nerd's factor model ranks Ionis Pharmaceuticals, Inc. 48 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ionis Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IONS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $66 to $115 over the next 12 months.
Ionis Pharmaceuticals, Inc. returned +33.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in RNA-targeted medicines, headquartered in Carlsbad, California and founded in 1989.
The most recent item we track (The Motley Fool, 14 Aug 2026): "Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?". Ionis stock has plunged 30%. The company's Q2 revenue fell, though last year's figures included a large one-time payment, and the earnings report also showed other signs of trouble.
Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in RNA-targeted medicines, headquartered in Carlsbad, California and founded in 1989. The company focuses on discovering and developing antisense oligonucleotide therapies and related RNA-directed technologies to treat serious and often rare diseases across neurology, cardiometabolic, and other high-need therapeutic areas. Ionis develops proprietary drug candidates on its antisense platform and uses a hybrid model: it commercializes certain rare-disease medicines directly or with co-promotion partners, while licensing other programs to larger pharmaceutical companies for broad late-stage development and global commercialization. Its marketed portfolio includes therapies for conditions such as spinal muscular atrophy, hereditary transthyretin-mediated amyloidosis, familial chylomicronemia syndrome, and SOD1-ALS, among others, reflecting its focus on targeted, mechanism-based treatments. Operating today as a fully integrated commercial-stage biotech with a deep clinical pipeline, Ionis plays a significant role in advancing RNA-based therapeutics within the global biopharmaceutical market.
CEO Dr. Brett P. Monia Ph.D. · 1,480 employees · United States · https://www.ionis.com